中国临床药理学杂志2016，Vol.32Issue(14)：1279-1282,4.DOI:10.13699/j.cnki.1001-6821.2016.14.009
埃索美拉唑联合生长抑素治疗重症胰腺炎的临床研究
Clinical trial of somatostatin combined with esomeprazole on patients with severe acute pancreatitis
摘要
Abstract
Objective To investigate the clinical effect of somatostatin combined with esomeprazole on patients with severe acute pancreatitis . Methods Eighty cases of severe acute pancreatitis patients were divided into treatment group (40 cases) and control group (40 cases) randomly. Treatment group was treated with somatostatin combined with esomeprazole treatment ( before 7 d, esomeprazole 40 mg intravenous injection , intrave-nous injection of somatostatin 3 mg, once a day , after 7 d, esomeprazole dose for 40 mg, 12h a time, somatostatin dose for 6 mg, 24h a time). The control group was treated with routine patients , such as fasting , gastrointestinal decompression , keeping the electrolyte and acid -base balance , inhibiting the secretion of pancreas and the nutrition of the patients.Observe the changes of intra-abdominal hypertension (IAH), plasma endotoxin (PE), D-lactate, diamine oxidase ( DAO) and urine amylase ( UAMY) before and after treatment in two groups , and compare the intestinal reco-very time, abdominal pain , abdominal distension , ease of time , the difference in length of hospital stay , the clinical efficacy and adverse reactions were observed.Results After treatment, the IAH in the treatment group was (11.48 ± 2.07) mmHg, lower than (13.98 ±2.45)mmHgin the control group (P<0.05).After treatment, the PE(3.21 ± 0.73 ) EU・ mL-1 , D -lactate ( 9.84 ±2.16 ) mg・ L-1 , DAO ( 2.78 ±0.83 ) ng・ L-1 , UAMY ( 6.47 ±1.43 ) U・ L-1 in treatment group were better than ( 5.54 ±1.01 ) EU・ mL-1 , ( 12.69 ±2.62 ) mg・ L-1 , ( 4.28 ±1.10 ) ng・ L-1,(9.79 ±1.95)U・ L-1 in control group(P<0.05).The intestinal recovery time, abdominal pain abdominal distension relief timeand hospitalization time intreatment group were (2.37 ±0.68),(1.94 ±0.52),(20.33 ±1.78) d, significantly shorter than (3.69 ±1.01),(3.45 ±0.94),(25.39 ±1.85)d in control group(P<0.05).The total effective rate in treatment group was 95.00% ( 38/40 ) , higher than that 75.00%( 30/40 ) in control group ( P<0.05 ) .The adverse reactions in treatment group were mainly dizziness and drowsiness , with the incidence of 5.00%(2/40).The adverse reactions in control group were mainly bloating , abdominal pain and nausea and vomi-ting, with the incidence of 17.50%(7/40, P<0.05).Conclusion The endostatin combined with esomeprazole had significantly effect in patients with severe acute pancreatitis , can reduce intra -abdominal hypertension , enhance the shielding function of intestinal mucosa , and is beneficial to the prognosis .关键词
重症胰腺炎/腹内高压/肠道黏膜屏障功能Key words
severe acute pancreatitis/intra-abdominal hypertension/intestinal mucosal barrier function分类
医药卫生引用本文复制引用
陈曦,孙霞,夏兴洲,王雪艳..埃索美拉唑联合生长抑素治疗重症胰腺炎的临床研究[J].中国临床药理学杂志,2016,32(14):1279-1282,4.基金项目
河南省科技攻关基金资助项目 （）
